Organigram Reports Q2 Fiscal 2026 Results

TORONTO – Organigram Global Inc. released its financial results, marking a quarter shaped by shifts in consumer preferences and execution issues in key categories. The Canadian producer, known for holding the top market share position domestically, reported declines in several core metrics while pointing to operational fixes and a major international move.

Net revenue fell to $59.8 million from $65.6 million in the same period last year, a 9% drop driven mainly by softer sales in vapes and infused pre-rolls. Gross revenue reached $93.3 million, also down 9%. International revenue held steady at $6.1 million. Adjusted EBITDA came in at $0.9 million, down sharply from $4.9 million a year earlier. The company recorded a net loss of about $0.9 million, compared with net income of $42.5 million in the prior-year quarter, partly due to smaller fair value gains and a $5.8 million impairment tied to its U.S. hemp-derived products business.

Management attributed much of the revenue shortfall to market share erosion in vapes, where consumer demand moved toward higher-potency options, and temporary production challenges with infused pre-rolls. Higher returns provisions and a shift toward lower-margin value products also weighed on margins. Adjusted gross margin stood at 31%, down from 33%. Selling, general and administrative expenses rose modestly to $23.6 million.

On the positive side, Organigram highlighted operational strengths. It achieved a record harvest exceeding 32,000 kilograms, up 56% year over year, along with its highest average THC potency at the Moncton facility. The company launched new vape and gummy products in Australia under the BOXHOT and Edison brands and continued work on powdery mildew-resistant cultivars.

In April, Organigram closed its acquisition of Sanity Group, a leading German Cannabis company. The deal is expected to add meaningful revenue starting in Q3 and expand the company’s footprint in European medical markets. Organigram raised its fiscal 2026 net revenue guidance to more than $350 million, up from a prior target above $300 million. It also expects adjusted EBITDA and adjusted gross margin to exceed last year’s levels, with free cash flow near breakeven and capital expenditures below $10 million.

CEO James Yamanaka noted that the company moved quickly to address Q2 issues through quality controls and product refreshes, with early signs of stabilization. CFO Greg Guyatt pointed to improving yields, efficiencies, and the upcoming Sanity contribution as supports for H2 2026.

Organigram maintains its position as Canada’s leading Cannabis company by market share across several categories, including vapes and milled flower. Its cash position stood at $54.8 million at quarter-end, with subsequent debt financing supporting the Sanity transaction.

All in all, the results reflect ongoing pressures in the Canadian recreational market alongside steps toward broader international scale. Within an industry still adjusting to the dynamics of legalisation, Organigram’s focus on improving cultivation and strategic acquisitions offers a measured path forward, even though near-term profitability remains under strain.